GC said Friday that it has received additional approval from the Ministry of Food and Drug Safety to expand the indication for GC Fluquadribalant, Korea’s first quadrivalent influenza vaccine, on infants aged six months to three years.

With the approval, the vaccine has become the first locally developed quadrivalent vaccine to cover all ages.

GC Fluquadribalant has maintained the biggest market share since its launch and was the only flu vaccine on the list of the top 10 biopharmaceutical production in Korea last year.

Also, it is the second quadrivalent vaccine in the world to qualify for a bid for the international organization procurement market through the prequalification certification provided by the World Health Organization (WHO).

GC plans to manufacture four million doses quadrivalent and five million trivalent vaccines for domestic supply this year.

“As the vaccine is available for all ages, it can contribute to reducing the social burden and cost of the annual influenza outbreak,” GC Vice President Kim Byung-hwa said.